Seer's Special Committee rejected acquisition proposals valued at $2.45 to $2.55 per share, deciding the offers undervalue the company. The company remains independent to capitalize on future AI-biology opportunities.
Seer's Special Committee rejected acquisition proposals valued at $2.45 to $2.55 per share, deciding the offers undervalue the company. The company remains independent to capitalize on future AI-biology opportunities.